Holen Sie sich die Stockscreener-App
19.34
3.64%
0.68
Handel nachbörslich:
19.56
0.22
+1.14%
Forte Biosciences Inc Aktie (FBRX) Neueste Nachrichten
(FBRX) Long Term Investment Analysis - Stock Traders Daily
Why Forte Biosciences (FBRX) Stock Is Trading Lower - Benzinga
Forte Biosciences, Inc. (NASDAQ:FBRX) Short Interest Update - Defense World
Invea Therapeutics Strengthens Leadership with Appointment of Dr. Stephen Doberstein, Veteran Biotech Executive, to Its Board of Directors - The Manila Times
Trading (FBRX) With Integrated Risk Controls - Stock Traders Daily
FBRX Stock Soars to 52-Week High, Reaching $24.46 By Investing.com - Investing.com Nigeria
Forte Biosciences’ $53 Million Equity Financing - Global Legal Chronicle
(FBRX) Trading Report - Stock Traders Daily
Here's Why Momentum in Forte Biosciences (FBRX) Should Keep going - MSN
FBRX Stock Soars to 52-Week High, Reaching $21.47 - Investing.com India
FBRX Stock Soars to 52-Week High, Reaching $21.47 By Investing.com - Investing.com UK
Forte Biosciences Sets R&D Day to Showcase FB102 Autoimmune Treatment Pipeline | FBRX Stock News - StockTitan
Forte Biosciences CFO acquires $124,997 in company stock By Investing.com - Investing.com Canada
Forte Biosciences CFO acquires $124,997 in company stock - Investing.com
More than $50M raised by publicly traded drug developer - The Business Journals
Dallas' Forte Biosciences Announces $53M Private Placement From Leading Healthcare Investors - dallasinnovates.com
Forte Biosciences Stock More Than Doubles On Oversubscribed $53M Private Placement: Retail Goes Wild - MSN
EDIT Stock Drops Amid Market Volatility in Biotech Sector - GuruFocus.com
Cidara’s $100M PIPE; Pyxis Oncology’s stock falls on Phase 1 data - Endpoints News
Stock market today: Pyxis Oncology plunges by 47.25% while Perspective Therapeutics declines by 46.68% in early trading - Business Upturn
Forte Biosciences secures $53 million in funding By Investing.com - Investing.com Canada
Lexicon Pharmaceuticals (LXRX) Stock Plummets Amidst Market Acti - GuruFocus.com
Artelo Biosciences (ARTL) Stock Surges Amid Strong Buy Ratings - GuruFocus.com
5 Stocks Retail Investors Are Most Bullish On At Mid-Day - MSN
Forte Biosciences Secures $53M for FB102 Advancements - TipRanks
Terns Pharmaceuticals (TERN) Stock Drops Over 5% Amidst Mixed In - GuruFocus.com
Forte Biosciences Shares Are Soaring Today: What's Going On? - Benzinga
Crude Oil Moves Lower; Williams-Sonoma Shares Gain After Q3 Results - Benzinga
Forte Biosciences secures $53 million in funding - Investing.com India
Forte Biosciences More Than Doubles on $53M Private Placement - MarketWatch
Stock Market News: Forte Biosciences +151.47%, Exicure +99.48% among top gainers during mid day trading - Business Upturn
Stock Market News: Ethan Allen Interiors down by 90.10% while Exicure gains 99.48% during mid day trading - Business Upturn
Nasdaq Tumbles Over 100 Points; TJX Earnings Top Views - Benzinga
Stock Market Today: Forte Biosciences up by 54.60% while Red Cat Holdings gains 35% in early trading - Business Upturn
Stock Market Today: Ethan Allen Interiors falls by nearly 90% while Forte Biosciences surges by 64.89% in early trading - Business Upturn
US Stocks Mostly Lower; Target Posts Downbeat Earnings - Benzinga
Thrive Tribe Technologies Affirms ASX Compliance Amid Stock Query - MSN
Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications - The Bakersfield Californian
Forte Biosciences Secures $53M Private Placement for Autoimmune Drug Development | FBRX Stock News - StockTitan
Forte Biosciences (FBRX) Upgraded to Buy: What Does It Mean for the Stock? - MSN
IBD Rating Upgrades: Chesapeake Utilities Flashes Improved Relative Price Strength - MSN
Celiac Disease Pipeline Grows as 25+ Key Pharma Companies Join the Fight for Innovative Treatments | DelveInsight - Lelezard
Forte Biosciences, Inc. announced that it expects to receive $53 million in funding from OrbiMed Advisors LLC, Janus Henderson Group plc, Tybourne Capital Management Limited, Ikarian Capital, LLC, BVF Partners L.P., Fred Alger Management, LLC - Marketscreener.com
When the Price of (FBRX) Talks, People Listen - Stock Traders Daily
Psyence Biomedical gets extension to show compliance with Nasdaq’s listing rules - MSN
Brown Advisory US Smaller Companies PLC Updates Office Location - MSN
Stephens & Co. Initiates Coverage of IDEAYA Biosciences (IDYA) with Overweight Recommendation - MSN
Forte Biosciences (NASDAQ:FBRX) Stock Price Expected to Rise, Chardan Capital Analyst Says - Defense World
Dairy Max Names Agriculture Industry Veteran as its New CEO - dallasinnovates.com
Forte Biosciences Inc reports results for the quarter ended September 30Earnings Summary - XM
Perceptive Advisors LLC Acquires Shares in Forte Biosciences Inc - GuruFocus.com
Forte Biosciences Inc (FBRX) Quarterly 10-Q Report - Quartzy
Forte Biosciences Inc. Reports Q3 2024 Earnings - TipRanks
Tocagen Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Forte Biosciences Advances Celiac Disease Trial as Q3 Losses Widen to $4.54/Share | FBRX Stock News - StockTitan
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):